Prevalence of Neurological Symptoms and Imaging Findings in Von Hippel–Lindau Patients Referred to Rasool Akram Hospital, 2018–2021

Main Article Content

Seyed Hamidreza Javadi
Seyed Amir Hassan Habibi
Ahad Sedaghat
Masood Naseripour
Mohammad Yousefi


Cerebellar tumors, Imaging findings, Neurological examination, Retinallesions, Von Hippel-Lindau


This study aimed to assess the prevalence of neurological symptoms and related imaging findings in patients with von Hippel-Lindau (VHL) at Rasool Akram Hospital from September 2018 to September 2021. This analytical observational study examined eligible patients over the period from September 2018 to September 2021. We collected demographic information (age, gender) along with imaging findings and results of neurological and eye examinations. Comparison between qualitative variables was also done using the Chi-square test or Fisher’s exact test. Also, an independent t-test was used to compare quantitative variables between the two groups. SPSS version 22 software was used for statistical analysis of data. A significant level was considered less than or equal to 0.05. Of the 54 examined patients (48.1% were male and 51.9% were female) with an average age of 36.42 ± 13.37 years. A significant majority (87.0%) reported a positive family history of the disease. The most common type of disease was Type 1 observed in 94.4% of cases and Type 2A was the next most frequent (3.7%). The most common pattern of retinal pathological lesions seen in the examination was related to bilateral lesions (79.6%). The most common pathological finding was related to the presence of a mass in cerebellar magnetic resonance imaging (48.1%). Considering the findings of the present study, which highlight a significant frequency of bilateral retinal lesions as well as masses in the central nervous system and endocrine system, it is evident that patients require careful follow-up and various interventions after being diagnosed with the disease. This approach is essential to manage and potentially mitigate the complications associated with these conditions.

Abstract 104 | PDF Downloads 65 HTML Downloads 0 XML Downloads 2


1. Maher ER, Neumann HP, Richard S. von Hippel–Lindau disease: A clinical and scientific review. European Journal of Human Genetics. 2011;19(6):617–23. 10.1038/ejhg.2010.175

2. Hickey MM, Lam JC, Bezman NA, Rathmell WK, Simon MC. von Hippel–Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2α signaling and splenic erythropoiesis. The Journal of clinical investigation. 2007;117(12):3879–89. 10.1172/JCI32614

3. Butman JA, Linehan WM, Lonser RR. Neurologic manifestations of von Hippel-Lindau disease. Jama. 2008;300(11):1334–42. 10.1001/jama.300.11.1334

4. Hes FJ, Höppener JWM, Luijt RBvd, Lips CJM. von Hippel-Lindau Disease. Hereditary Cancer in Clinical Practice. 2005;3(4):171.

5. Naseripour M, Azimi F, Talebi S, Mirshahi R, Kiaee R, Sedaghat A, et al. Investigation of germline VHL variants in Iranian patients with retinal capillary hemangioblastoma and genotype-phenotype analysis. Ophthalmic genetics. 2023;44(3):211–17. 10.1080/13816810.2022.2138455

6. Karimi S, Arabi A, Shahraki T, Safi S. von Hippel-Lindau disease and the eye. Journal of ophthalmic & vision research. 2020;15(1):78. 10.18502/jovr.v15i1.5950

7. Singh AD, Shields CL, Shields JA. von Hippel–Lindau disease. Survey of ophthalmology. 2001;46(2):117–42. 10.1016/s0039-6257(01)00245-4

8. Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS. A Review of Von Hippel-Lindau Syndrome. J Kidney Cancer VHL. 2017;4(3):20–29.

9. Wong WT, Agrón E, Coleman HR, Tran T, Reed GF, Csaky K, et al. Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel–Lindau disease. Ophthalmology. 2008;115(1):181–88. 10.1016/j.ophtha.2007.03.009

10. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. The Lancet. 2003;361(9374):2059–67. 10.1016/S0140-6736(03)13643-4

11. Chittiboina P, Lonser RR. von Hippel–Lindau disease. Handbook of clinical neurology. 2015;132:139–56. 10.1016/B978-0-444-62702-5.00010-X

12. Maher ER. von Hippel-Lindau disease. European Journal of Cancer. 1994;30(13):1987–90. 10.1016/0959-8049(94)00391-h

13. Ashouri K, Mohseni S, Tourtelot J, Sharma P, Spiess PE. Implications of Von Hippel-Lindau syndrome and renal cell carcinoma. J Kidney Cancer VHL. 2015;2(4):163. 10.15586/jkcvhl.2015.41

14. Cassol C, Mete O. Endocrine manifestations of von Hippel–Lindau disease. Archives of Pathology and Laboratory Medicine. 2015;139(2):263–68. 10.5858/arpa.2013-0520-RS

15. Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER. Genotype–phenotype correlations in von Hippel-Lindau disease. Human mutation. 2007;28(2):143–49. 10.1002/humu.20385

16. Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–75. 10.1038/20459

17. Neumann HP, Dinkel E, Brambs H, Wimmer B, Friedburg H, Volk B, et al. Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology. 1991;101(2):465–71. 10.1016/0016-5085(91)90026-h